Taysha Gene Therapies/$TSHA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
- Ticker
- $TSHA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 99
- Headquarters
- Dallas, United States
- Website
- www.tayshagtx.com
TSHA Metrics
BasicAdvanced
$1.3B
-
-$0.41
1.19
-
Price and volume
Market cap
$1.3B
Beta
1.19
52-week high
$7.30
52-week low
$3.46
Average daily volume
4.2M
Financial strength
Current ratio
17.765
Quick ratio
17.533
Long term debt to equity
0.143
Total debt to equity
0.146
Interest coverage (TTM)
-3,646.64%
Profitability
EBITDA (TTM)
-151.988
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-2,728.04%
Operating margin (TTM)
-2,792.32%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-23.82%
Return on equity (TTM)
-47.05%
Valuation
Price to revenue (TTM)
272.409
Price to book
3.47
Price to tangible book (TTM)
3.47
Price to free cash flow (TTM)
-11.021
Free cash flow yield (TTM)
-9.07%
Free cash flow per share (TTM)
-0.375
Growth
Revenue change (TTM)
-32.27%
Earnings per share change (TTM)
23.11%
3-year revenue growth (CAGR)
-17.03%
3-year earnings per share growth (CAGR)
-42.73%
What the Analysts think about TSHA
Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.
Analyst projections of the future price of Taysha Gene Therapies stock.
Bulls say / Bears say
In the 12-patient Part A cohort, all participants had gained or regained at least one developmental milestone by 12 months, and milestone gains continued to increase with longer follow-up. Taysha also reported no treatment-related serious adverse events or dose-limiting toxicities across 29 treated patients as of June. (GlobeNewswire)
Dosing is complete in the 17-patient REVEAL pivotal trial, and Taysha says the FDA has aligned on a pathway that could allow a six-month interim analysis to support a BLA. Interim results and FDA feedback are expected in the first half of 2027, creating a clear regulatory catalyst. (GlobeNewswire)
Taysha reported $455.4 million in cash at the end of June and expects its runway to extend into the second half of 2028. It has also secured Catalent as its primary commercial manufacturing partner, helping prepare supply if TSHA-102 is approved. (StockTitan, Investing News Network)
The efficacy evidence is still based on a small early-stage cohort: Part A had 12 patients, while the pivotal study is a 17-patient, single-arm trial. Without a concurrent control group, results may be sensitive to patient variation and the choice of milestone endpoint. (GlobeNewswire, BioSpace)
The regulatory timeline remains dependent on future milestones: pivotal interim results and FDA feedback are not expected until the first half of 2027, while manufacturing qualification was still targeted for completion in the fourth quarter of 2026. Delays or unfavourable feedback could push back a filing and any launch. (GlobeNewswire, Last10K)
The company funded much of its longer runway through a $230 million follow-on offering that included common shares and pre-funded warrants, diluting existing holders. Meanwhile, its second-quarter net loss widened to $46.6 million from $26.9 million a year earlier as research and development costs rose. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2026.
TSHA Financial Performance
Revenues and expenses
TSHA Earnings Performance
Company profitability
Upcoming events
No upcoming events
TSHA News
AllArticlesVideos
Funds containing TSHA
Fund name | Fund size | $TSHA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.10% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.10% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.10% |
iShares Ageing Population$AGED | $953M | 0.09% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.